Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240538 · ClinicalTrials.gov registry record · Phase 1
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01240538: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01240538 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01240538, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of viral therapy in treating young patients with solid tumors that have come back or that have not responded to standard therapy. Some tumors have cells with a genetic weakness that makes them unable to fight off a virus called wild-type reovirus. The virus causes cells with this weakness to die, and may therefore be able to kill tumor cells without damaging normal cells. Cyclophosphamide is a drug used in chemotherapy that stops tumor cells from dividing and causes them to die. Giving wild-type reovirus together with cyclophosphamide may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- OTHER pharmacological study
- BIOLOGICAL wild-type reovirus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240538
The ClinicalTrials.gov registry entry for NCT01240538 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01240538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240538 about?
NCT01240538 is a clinical study titled "Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors". This phase I trial studies the side effects and the best dose of viral therapy in treating young patients with solid tumors that have come back or that have not responded to standard therapy. Some tumors have cells with a genetic weakness that makes them unable to fight off a virus called wild-type ...
What is the current status of trial NCT01240538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-12.
What interventions are being tested in trial NCT01240538?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), pharmacological study (OTHER), wild-type reovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT01240538?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.